Trial · NCT06473597
A Comparison of Nurtec ODT to Maxalt MLT-ODT in Adult ED Patients With Migraine Headache
NCT06473597, Phase 4, Recruiting, Antonios Likourezos
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Comparison of Nurtec ODT to Maxalt MLT-ODT in Adult ED Patients With Migraine Headache. Trials, record NCT06473597. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06473597
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Comparison of Nurtec ODT to Maxalt MLT-ODT in Adult ED Patients With Migraine Headache
- NCT number
- NCT06473597
- Status
- Recruiting
- Phases
- Phase 4
- Enrollment
- 80 participants, estimated
- Lead sponsor
- Antonios Likourezos
- Conditions
- Migraine
- Interventions
- Rimegepant, Rizatriptan Benzoate
- First posted
- 2024-06-25
- Last updated
- 2026-09-24
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Pain Score at 60 minutes | 60 minutes | Change in Pain Score between baseline and 60 minutes. Pain score will be measured via validated an 11 point Likert Scale where 0 is no pain, 5 moderate pain and 10 very severe pain. |
| Secondary | Change in Pain Score | 120 minutes | Change in Pain Score between baseline and 120 minutes. Pain score will be measured via validated an 11 point Likert Scale where 0 is no pain, 5 moderate pain and 10 very severe pain. |
| Secondary | Rescue Analgesia at 60 minutes | 60 minutes | Frequency of Rescue Analgesia at 60 minutes |
| Secondary | Rescue Analgesia at 120 minutes | 120 minutes | Frequency of Rescue Analgesia at 120 minutes |
| Secondary | Percentage of Patients who Sustained Headache Freedom | 24 hours | Sustained headache freedom, defined as achieving a level of "none" on the severe, moderate, mild, and none scale within 2 hours of investigational medication administration and maintaining this level continuously for 24 hours without use of rescue medication. |
| Secondary | Percentage of Patients Who Sustained Headache Relief | 24 hours | Sustained headache relief, defined as change within 2 hours of the patient's description of headache from severe or moderate to either mild or none without use of rescue medication, and maintaining this level of relief continuously for 24 hours. |
| Secondary | Percentage of Patients who had Headache Relief In the ED | 2 hours | Headache relief in the ED, defined as change within 2 hours of the patient's description of headache from severe or moderate to either mild or none without the use of rescue medication |
| Secondary | Percentage of Patients with Headache Freedom in the ED | 2 hours | Headache freedom in the ED, defined as achieving a headache level of "none" within 2 hours without use of rescue medication |
| Secondary | Functional Status | 2 hours | Achieving a normal functional status by two hours |
| Secondary | Headache Medication Efficacy and Tolerability Perception by the Patient | 2 hours | The patient's overall assessment of efficacy and tolerability, expressed as a dichotomous response to the question "Do you want to receive the same medication the next time you visit the ER with a migraine?" |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06473597
GET https://conductscience.org/api/trials/v1/NCT06473597/registered